Send to a Friend Font Size: Increase Decrease

Highbridge Capital

Highbridge Capital's Portfolio

Ticker	# of Shares	Price	Value
	75,000,000	$195.32	$14,649,000,000
	72,000,000	$195.32	$14,063,040,000
	65,000,000	$195.32	$12,695,800,000
	65,000,000	$195.32	$12,695,800,000
	63,500,000	$195.32	$12,402,820,000
	56,358,000	$195.32	$11,007,844,560
	54,470,000	$195.32	$10,639,080,400
	54,248,000	$195.32	$10,595,719,360
	48,500,000	$195.32	$9,473,020,000
	47,386,000	$195.32	$9,255,433,520
View Additional Portfolio Information »

Highbridge Capital

Login to help us fill in information about this entity.

Form SCHEDULE 13G BioLineRx Ltd. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC Aug 14, 2025 04:07PM

BioLineRx (BLRX) Issues Letter to Shareholders Jan 21, 2025 07:01AM

BioLineRx Issues Letter to Shareholders Jan 21, 2025 07:00AM

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value Nov 25, 2024 07:00AM

BioLineRx (BLRX) and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA Nov 21, 2024 06:31AM

Nov 21, 2024 06:30AM BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.